Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the development of tests for various types of cancers. The company’s flagship product, Cologuard test is a US FDA-approved non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of colorectal cancer and pre-cancer. It uses a multi-target approach to detect DNA and hemoglobin biomarkers related to colorectal cancer. The company also offers Oncotype DX gene expression tests for prostate, breast, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test designed for advanced stage prostate cancer. It operates manufacturing and laboratory facilities in Madison, Wisconsin to process Cologuard tests. Exact Sciences is headquartered in Madison, Wisconsin, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Exact Sciences Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Exact Sciences Corp Company Overview
- Exact Sciences Corp Company Snapshot
- Exact Sciences Corp Pipeline Products and Ongoing Clinical Trials Overview
- Exact Sciences Corp - Pipeline Analysis Overview
- Business Description
- Exact Sciences Corp - Key Facts
- Exact Sciences Corp - Major Products and Services
- Exact Sciences Corp Pipeline Products by Development Stage
- Exact Sciences Corp Ongoing Clinical Trials by Trial Status
- Exact Sciences Corp Pipeline Products Overview
- ActiveTargeting Assay
- ActiveTargeting Assay Product Overview
- Blood Based Colorectal Cancer Screening Test
- Blood Based Colorectal Cancer Screening Test Product Overview
- Blood-based Lung Cancer Screening Test
- Blood-based Lung Cancer Screening Test Product Overview
- Cancerguard
- Cancerguard Product Overview
- CancerSEEK Test
- CancerSEEK Test Product Overview
- Circulating Tumor DNA Test - Colorectal Cancer
- Circulating Tumor DNA Test - Colorectal Cancer Product Overview
- Circulating Tumor DNA Test - Colorectal Cancer Clinical Trial
- Cologuard 2.0
- Cologuard 2.0 Product Overview
- Diagnostic Assay - Liver Cancer
- Diagnostic Assay - Liver Cancer Product Overview
- Diagnostic Test - Breast Cancer
- Diagnostic Test - Breast Cancer Product Overview
- Diagnostic Test - Hepatocellular Carcinoma
- Diagnostic Test - Hepatocellular Carcinoma Product Overview
- Diagnostic Test - Lung Cancer
- Diagnostic Test - Lung Cancer Product Overview
- Diagnostic Test - Non Small Cell Lung Cancer
- Diagnostic Test - Non Small Cell Lung Cancer Product Overview
- Diagnostic Test - Prostate Cancer
- Diagnostic Test - Prostate Cancer Product Overview
- DNA Integrity Assay
- DNA Integrity Assay Product Overview
- DNA Methylation Based Blood Test - Cancer
- DNA Methylation Based Blood Test - Cancer Product Overview
- DNA Methylation Based Blood Test - Minimal Residual Disease
- DNA Methylation Based Blood Test - Minimal Residual Disease Product Overview
- Idylla IVD Oncotype DX Breast Recurrence Score Test
- Idylla IVD Oncotype DX Breast Recurrence Score Test Product Overview
- Idylla IVD Oncotype DX Breast Recurrence Score Test Clinical Trial
- Liquid Biopsy Test - Bladder Cancer
- Liquid Biopsy Test - Bladder Cancer Product Overview
- Liquid Biopsy Test - Breast Cancer
- Liquid Biopsy Test - Breast Cancer Product Overview
- Liquid Biopsy Test - Cervical Cancer
- Liquid Biopsy Test - Cervical Cancer Product Overview
- Liquid Biopsy Test - Esophageal Cancer
- Liquid Biopsy Test - Esophageal Cancer Product Overview
- Liquid Biopsy Test - Kidney Cancer
- Liquid Biopsy Test - Kidney Cancer Product Overview
- Liquid Biopsy Test - Lymphoma
- Liquid Biopsy Test - Lymphoma Product Overview
- Liquid Biopsy Test - Melanoma
- Liquid Biopsy Test - Melanoma Product Overview
- Liquid Biopsy Test - Ovarian Cancer
- Liquid Biopsy Test - Ovarian Cancer Product Overview
- Liquid Biopsy Test - Pancreatic Cancer
- Liquid Biopsy Test - Pancreatic Cancer Product Overview
- Liquid Biopsy Test - Prostate Cancer
- Liquid Biopsy Test - Prostate Cancer Product Overview
- Liquid Biopsy Test - Stomach Cancer
- Liquid Biopsy Test - Stomach Cancer Product Overview
- Liquid Biopsy Test - Uterine Cancer
- Liquid Biopsy Test - Uterine Cancer Product Overview
- Liquid Biopsy-Based Bladder Cancer Test
- Liquid Biopsy-Based Bladder Cancer Test Product Overview
- LungVantage Test
- LungVantage Test Product Overview
- MAESTRO Test
- MAESTRO Test Product Overview
- Multi-Cancer Earlier Detection Test
- Multi-Cancer Earlier Detection Test Product Overview
- Multi-Cancer Screening Test
- Multi-Cancer Screening Test Product Overview
- Negative Biopsy Test - Prostate Cancer
- Negative Biopsy Test - Prostate Cancer Product Overview
- Next Generation Sequencing Oncotype DX - Prostate Cancer Assay
- Next Generation Sequencing Oncotype DX - Prostate Cancer Assay Product Overview
- Oncofind
- Oncofind Product Overview
- Oncoguard Esophagus Test
- Oncoguard Esophagus Test Product Overview
- Oncosearch
- Oncosearch Product Overview
- Oncotype Dx - Kidney Cancer
- Oncotype Dx - Kidney Cancer Product Overview
- Oncotype SEQ - Tissue Mutation Panel
- Oncotype SEQ - Tissue Mutation Panel Product Overview
- Oncotype TRACK
- Oncotype TRACK Product Overview
- Oncoverify
- Oncoverify Product Overview
- Oncowatch
- Oncowatch Product Overview
- PapSEEK
- PapSEEK Product Overview
- Prognostic Test - Melanoma
- Prognostic Test - Melanoma Product Overview
- Prognostic Test - Non-Metastatic Renal Cell Carcinoma
- Prognostic Test - Non-Metastatic Renal Cell Carcinoma Product Overview
- Riskguard Minimal Residual Disease Test
- Riskguard Minimal Residual Disease Test Product Overview
- Riskguard Prognosis/Therapy Guidance Test
- Riskguard Prognosis/Therapy Guidance Test Product Overview
- Riskguard Recurrence Monitoring Test
- Riskguard Recurrence Monitoring Test Product Overview
- TARDIS Test
- TARDIS Test Product Overview
- UroSeqS
- UroSeqS Product Overview
- Viomics Diagnostic Assay - Breast Cancer
- Viomics Diagnostic Assay - Breast Cancer Product Overview
- Viomics Diagnostic Assay - Colon Cancer
- Viomics Diagnostic Assay - Colon Cancer Product Overview
- Viomics Diagnostic Assay - Pancreatic Cancer
- Viomics Diagnostic Assay - Pancreatic Cancer Product Overview
- Exact Sciences Corp - Key Competitors
- Exact Sciences Corp - Key Employees
- Exact Sciences Corp - Key Employee Biographies
- Exact Sciences Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Exact Sciences Corp, Recent Developments
- Jul 08, 2024: Exact Sciences Schedules Second Quarter 2024 Earnings Call
- May 21, 2024: Court Ruling Enables Exact Sciences to Proceed With Lawsuit Against Geneoscopy
- May 15, 2024: Foundation Fighting Blindness Partners with PreventionGenetics and InformedDNA to Advance My Retina Tracker Genetic Testing Program
- May 10, 2024: The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences’ Oncotype DX Test to Help Guide Chemotherapy Decisions for Node-Positive Breast Cancer Patients
- May 07, 2024: Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW 2024
- Apr 15, 2024: Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
- Apr 08, 2024: Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
- Mar 29, 2024: Workflow Services Partners with Exact Sciences to Provide Colorectal Cancer Screening for Patients with Access Challenges at the Pharmacy
- Mar 28, 2024: Exact Sciences Advances Development of Non-endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-cancer
- Mar 13, 2024: The New England Journal of Medicine Publishes Cologuard Plus Test Results from Pivotal BLUE-C Study
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Exact Sciences Corp Pipeline Products and Ongoing Clinical Trials Overview
- Exact Sciences Corp Pipeline Products by Equipment Type
- Exact Sciences Corp Pipeline Products by Indication
- Exact Sciences Corp Ongoing Clinical Trials by Trial Status
- Exact Sciences Corp, Key Facts
- Exact Sciences Corp, Major Products and Services
- Exact Sciences Corp Number of Pipeline Products by Development Stage
- Exact Sciences Corp Pipeline Products Summary by Development Stage
- Exact Sciences Corp Ongoing Clinical Trials by Trial Status
- Exact Sciences Corp Ongoing Clinical Trials Summary
- ActiveTargeting Assay - Product Status
- ActiveTargeting Assay - Product Description
- Blood Based Colorectal Cancer Screening Test - Product Status
- Blood Based Colorectal Cancer Screening Test - Product Description
- Blood-based Lung Cancer Screening Test - Product Status
- Blood-based Lung Cancer Screening Test - Product Description
- Cancerguard - Product Status
- Cancerguard - Product Description
- CancerSEEK Test - Product Status
- CancerSEEK Test - Product Description
- Circulating Tumor DNA Test - Colorectal Cancer - Product Status
- Circulating Tumor DNA Test - Colorectal Cancer - Product Description
- Circulating Tumor DNA Test - Colorectal Cancer - CORRECT-MRD I: First Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
- Circulating Tumor DNA Test - Colorectal Cancer - CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
- Cologuard 2.0 - Product Status
- Cologuard 2.0 - Product Description
- Diagnostic Assay - Liver Cancer - Product Status
- Diagnostic Assay - Liver Cancer - Product Description
- Diagnostic Test - Breast Cancer - Product Status
- Diagnostic Test - Breast Cancer - Product Description
- Diagnostic Test - Hepatocellular Carcinoma - Product Status
- Diagnostic Test - Hepatocellular Carcinoma - Product Description
- Diagnostic Test - Lung Cancer - Product Status
- Diagnostic Test - Lung Cancer - Product Description
- Diagnostic Test - Non Small Cell Lung Cancer - Product Status
- Diagnostic Test - Non Small Cell Lung Cancer - Product Description
- Diagnostic Test - Prostate Cancer - Product Status
- Diagnostic Test - Prostate Cancer - Product Description
- DNA Integrity Assay - Product Status
- DNA Integrity Assay - Product Description
- DNA Methylation Based Blood Test - Cancer - Product Status
- DNA Methylation Based Blood Test - Cancer - Product Description
- DNA Methylation Based Blood Test - Minimal Residual Disease - Product Status
- DNA Methylation Based Blood Test - Minimal Residual Disease - Product Description
- Idylla IVD Oncotype DX Breast Recurrence Score Test - Product Status
- Idylla IVD Oncotype DX Breast Recurrence Score Test - Product Description
- Idylla IVD Oncotype DX Breast Recurrence Score Test - A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-positive and HER2-negative Breast Cancer with Recurrence Score (Rs) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
- Liquid Biopsy Test - Bladder Cancer - Product Status
- Liquid Biopsy Test - Bladder Cancer - Product Description
- Liquid Biopsy Test - Breast Cancer - Product Status
- Liquid Biopsy Test - Breast Cancer - Product Description
- Liquid Biopsy Test - Cervical Cancer - Product Status
- Liquid Biopsy Test - Cervical Cancer - Product Description
- Liquid Biopsy Test - Esophageal Cancer - Product Status
- Liquid Biopsy Test - Esophageal Cancer - Product Description
- Liquid Biopsy Test - Kidney Cancer - Product Status
- Liquid Biopsy Test - Kidney Cancer - Product Description
- Liquid Biopsy Test - Lymphoma - Product Status
- Liquid Biopsy Test - Lymphoma - Product Description
- Liquid Biopsy Test - Melanoma - Product Status
- Liquid Biopsy Test - Melanoma - Product Description
- Liquid Biopsy Test - Ovarian Cancer - Product Status
- Liquid Biopsy Test - Ovarian Cancer - Product Description
- Liquid Biopsy Test - Pancreatic Cancer - Product Status
- Liquid Biopsy Test - Pancreatic Cancer - Product Description
- Liquid Biopsy Test - Prostate Cancer - Product Status
- Liquid Biopsy Test - Prostate Cancer - Product Description
- Liquid Biopsy Test - Stomach Cancer - Product Status
- Liquid Biopsy Test - Stomach Cancer - Product Description
- Liquid Biopsy Test - Uterine Cancer - Product Status
- Liquid Biopsy Test - Uterine Cancer - Product Description
- Liquid Biopsy-Based Bladder Cancer Test - Product Status
- Liquid Biopsy-Based Bladder Cancer Test - Product Description
- LungVantage Test - Product Status
- LungVantage Test - Product Description
- MAESTRO Test - Product Status
- MAESTRO Test - Product Description
- Multi-Cancer Earlier Detection Test - Product Status
- Multi-Cancer Earlier Detection Test - Product Description
- Multi-Cancer Screening Test - Product Status
- Multi-Cancer Screening Test - Product Description
- Negative Biopsy Test - Prostate Cancer - Product Status
- Negative Biopsy Test - Prostate Cancer - Product Description
- Next Generation Sequencing Oncotype DX - Prostate Cancer Assay - Product Status
- Next Generation Sequencing Oncotype DX - Prostate Cancer Assay - Product Description
- Oncofind - Product Status
- Oncofind - Product Description
- Oncoguard Esophagus Test - Product Status
- Oncoguard Esophagus Test - Product Description
- Oncosearch - Product Status
- Oncosearch - Product Description
- Oncotype Dx - Kidney Cancer - Product Status
- Oncotype Dx - Kidney Cancer - Product Description
- Oncotype SEQ - Tissue Mutation Panel - Product Status
- Oncotype SEQ - Tissue Mutation Panel - Product Description
- Oncotype TRACK - Product Status
- Oncotype TRACK - Product Description
- Oncoverify - Product Status
- Oncoverify - Product Description
- Oncowatch - Product Status
- Oncowatch - Product Description
- PapSEEK - Product Status
- PapSEEK - Product Description
- Prognostic Test - Melanoma - Product Status
- Prognostic Test - Melanoma - Product Description
- Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Status
- Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Description
- Riskguard Minimal Residual Disease Test - Product Status
- Riskguard Minimal Residual Disease Test - Product Description
- Riskguard Prognosis/Therapy Guidance Test - Product Status
- Riskguard Prognosis/Therapy Guidance Test - Product Description
- Riskguard Recurrence Monitoring Test - Product Status
- Riskguard Recurrence Monitoring Test - Product Description
- TARDIS Test - Product Status
- TARDIS Test - Product Description
- UroSeqS - Product Status
- UroSeqS - Product Description
- Viomics Diagnostic Assay - Breast Cancer - Product Status
- Viomics Diagnostic Assay - Breast Cancer - Product Description
- Viomics Diagnostic Assay - Colon Cancer - Product Status
- Viomics Diagnostic Assay - Colon Cancer - Product Description
- Viomics Diagnostic Assay - Pancreatic Cancer - Product Status
- Viomics Diagnostic Assay - Pancreatic Cancer - Product Description
- Exact Sciences Corp, Key Employees
- Exact Sciences Corp, Key Employee Biographies
- Exact Sciences Corp, Subsidiaries
- Glossary
- Exact Sciences Corp Pipeline Products by Equipment Type
- Exact Sciences Corp Pipeline Products by Development Stage
- Exact Sciences Corp Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Veracyte Inc
- Mainz Biomed NV
- Epigenomics AG
- Natera Inc
- Freenome Inc
- EDP Biotech Corporation
- Agendia Inc
- Myriad Genetics Inc
- Grail LLC
